Noxopharm (ASX:NOX) has announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences.
Interim results from the DARRT-1 study were first released to financial markets earlier this year.
According to the company, these results showed that patients who were treated with its proprietary treatment Veyonda combined with radiotherapy had a durable anti-cancer response rate lasting at least six months in a high proportion of men with end-stage, metastatic, castration-resistant prostate cancer (mCRCP).
The DARRT-1 interim results will be displayed in a poster presentation at the Clinical Oncology Society of Australia (COSA) annual scientific meeting in November this year. Sydney-based St Vincents Hospital will also present a poster related to their LuPIN study. This study is an investigator-initiated clinical trial looking at the effect of Veyonda in combination with a new cancer treatment 177LuPSMA-617 in men with mCRPC.
Noxopharm said it will also have an e-publication on the DARRT-1 interim results included in the proceedings for the annual meeting of the Chinese Society of Clinical Oncology (CSCO) commencing later thisi week. The CSCO has over 10,000 members and this meeting includes international sessions that present the latest cancer care strategy and research results.
Greg van Wyk, Noxopharm CEO and chief medical officer, said: "Inclusion of our DARRT-1 study results in these important medical conferences is indeed validation of the work we have underway. Our abstracts have been peer-reviewed and found to be of value to oncologists both in Australia and overseas."